GlassScriptPhysician profile
Mark J Polatnick
NPI 1376562090
$15,044.34
in general payments reported to CMS, 2019-2025
49 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $1,453 · 2021: $2,782 · 2022: $2,164 · 2023: $2,640 · 2024: $2,559 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,758.21 |
| Education | $326.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,571.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,488.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,279.25 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,158.46 | 2019-2025 | |
| Lilly USA, LLC | $1,130.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,071.21 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $884.50 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Sanofi-Aventis U.S. LLC | $871.01 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $785.64 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Janssen Pharmaceuticals, INC | $571.78 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $389.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.25 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $321.12 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $235.77 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $230.48 | 2019-2025 | Verquvo, Lagevrio, Belsomra |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Polatnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.